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OBJECTIVES We studied the association of the PlA1/A2 polymorphism with coronary thrombosis, myocardial
infarction (MI) and sudden cardiac death (SCD) in autopsied victims of sudden death.
BACKGROUND Sudden cardiac death is one of the leading symptoms of coronary heart disease in early middle
age. Platelet glycoprotein (GP)IIb/IIIa fibrinogen receptors play a key role in coronary
thrombosis and MI. PlA1/A2 polymorphism of the gene for GPIIIa has been previously
studied in hospital MI patients. Significance of the PlA1/A2 polymorphism in victims of SCD
is not known.
METHODS The PlA1/A2 polymorphism was studied in the Helsinki Sudden Death Study comprising 700
autopsied middle-aged white Finnish men (33 to 70 years, mean 53 years) who suffered
sudden or violent out-of-hospital death.
RESULTS Prevalence of the A2 allele decreased with age in the series. This decrease was observed
among victims of SCD (n 5 281) but not in men who died violently (n 5 258) or of other
diseases (n 5 127). Of SCD victims below 50 years, 39.7% were carriers of the A2 allele
compared with 28.3% among men under 50 who died of other causes (odds ratio [OR] 2.5,
p 5 0.01). Men with acute fatal coronary thrombosis (n 5 39) were more often (OR 3.4, p ,
0.01) carriers of the A2 allele than were men (n 5 242) with SCD in the absence of acute
coronary thrombosis (48.7% vs. 24.4%, respectively). In addition, men with MI and recent or
old thrombosis (n 5 67) were more often (OR 3.6, p 5 0.005) carriers of the A2 allele than
were men (n 5 123) with MI in the absence of thrombosis (44.8% vs. 20.3%, respectively).
These associations were especially strong in men under 60.
CONCLUSIONS Our results suggest that the A2 allele of the PlA1/A2 polymorphism of GPIIIa is a major risk
factor of coronary thrombosis and may be one important predictor of SCD in early middle
age. (J Am Coll Cardiol 2000;36:1317–23) © 2000 by the American College of Cardiology
Sudden death is one of the main complications of coronary
heart disease (CHD). Approximately 50% of deaths caused
by CHD are sudden and take place outside a hospital (1,2).
Moreover, in 20% to 25% of all cases of CHD, sudden
death is the first and only manifestation of the disease (2),
being the leading first symptom of CHD in early middle age
(3,4). Knowledge of factors predisposing to sudden cardiac
death (SCD) instead of stable CHD is very limited. Factors
that may increase the risk of SCD are cigarette smoking
(5–8) and parental history of myocardial infarction (MI) (6)
or sudden death (9).
Fissuring or rupture of an atheromatous plaque, subsequent
platelet aggregation and thrombus formation are key events in
the development of acute myocardial infarction (AMI) and
sudden death in patients with CHD (10–14), even though an
acute myocardial lesion can only be found in approximately
half of the victims of SCD, the deaths in the other half being
due to arrhythmias arising from old infarct scars (2).
Acute occluding thrombosis is usually associated with
transmural MI, whereas subendocardial MI often results
from slower platelet-dependent progression of preexisting
coronary narrowings (15–19). These two phenotypes of MI
are clinically often presented as Q-wave and non-Q wave
infarctions, respectively (20).
Platelet glycoprotein (GP)IIb/IIIa fibrinogen receptors are
activated and begin binding fibrinogen after rupture or fissur-
ing of coronary plaques, resulting in platelet aggregation and
thrombus formation. In addition to platelets, GPIIIa is abun-
dantly expressed in endothelium and in vascular smooth
muscle cells (vSMC) (21,22). PlA1/A2 polymorphism of the
gene for GPIIIa is responsible for a change in the protein
conformation and the spatial orientation of the ligand-binding
region (23). Studies on the effect of the PlA1/A2 polymorphism
on platelet function in vitro (24–28) have suggested that the
polymorphism is functional, whereas studies on the association
of the PlA1/A2 polymorphism with MI have aroused remark-
able controversy (29–47).
In our previous study (29), we found that the PlA2 allele
was associated with MI because of coronary thrombosis. In
the present study, we extended our previous study popula-
tion to include another large autopsy series in order to
further study the significance and age-dependency of the
PlA1/A2 polymorphism in victims of SCD.
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METHODS
Prospective autopsy series of middle-aged men. Helsinki
Sudden Death Study (HSDS) was designed to study the
risk factors of sudden out-of-hospital cardiac death and can
be conceived as a complementary study to the national
WHO MONICA Project (1,48). The HSDS study com-
prised two prospective consecutive series of a total of 700
white Finnish men, who were subjected to a medicolegal
autopsy at the Department of Forensic Medicine, University
of Helsinki, in 1981 to 1982, and 10 years later in 1991 to
1992. The mean age in both series was 53 years (range 33 to
70). The reason for the medicolegal autopsy was unexpected
sudden death occurring outside a hospital, often unob-
served. In Finland, all cases of sudden out-of-hospital
cardiac death must be subjected to medicolegal autopsy; this
includes more than 40% of the total deaths in the studied
age group. Thus, all men aged 33 to 70 who suffered sudden
cardiac death outside hospital during the study years are
included in this study. Causes of deaths were as follows:
cardiac causes in 41.1% (n 5 288), of which 230 (79.9%)
were due to CHD without valvular disease, significant
cardiomyopathy or other cardiac diseases; other diseases in
20.0% (n 5 140) and suicides or accidents in 38.9% (n 5
272). Characteristics of the study population are shown in
Table 1. The study was approved by the Ethics Committee
of The Department of Forensic Medicine, University of
Helsinki.
Characteristics and phenotypes of MI. The presence of
MI in the series was confirmed by macroscopic and histo-
logic examination of the myocardium. The presence/
absence of neutrophil granulocytes was considered diagnos-
tic of an acute MI and the presence/absence of fibrous scar
tissue diagnostic of an old MI. Based on the autopsy
findings and nitro-blue-tetrazolium (NBT) staining (49),
the MI was classified as either transmural or non-
transmural. The presence of recent or organizing macro-
scopic coronary thrombosis was recorded while the coronary
arteries were opened.
In 700 men, a total of 184 were found to have MI.
Eighty-five men died of AMI with or without an old MI.
Of the AMI cases, 39 were associated with coronary
thrombosis, of which 24 were acute. Old nonfatal MI scar
without AMI was found in an additional 99 cases, of which
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
BMI 5 body mass index
CHD 5 coronary heart disease
GPIIIa 5 glycoprotein IIIa
HSDS 5 Helsinki Sudden Death Study
MI 5 myocardial infarction
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PHS 5 Physicians’ Health Study
SCD 5 sudden cardiac death
vSMC 5 vascular smooth muscle cells
Ta
bl
e
1.
C
ha
ra
ct
er
is
tic
s
of
th
e
D
ec
ea
se
d
in
R
el
at
io
n
to
C
au
se
s
of
D
ea
th
V
ar
ia
bl
e
A
ll
U
nd
er
60
Su
dd
en
C
ar
di
ac
D
ea
th
(n
5
28
8)
V
io
le
nt
D
ea
th
(n
5
27
2)
O
th
er
D
is
.
(n
5
14
0)
p
V
al
ue
Su
dd
en
C
ar
di
ac
D
ea
th
(n
5
17
8)
V
io
le
nt
D
ea
th
(n
5
23
4)
O
th
er
D
is
.
(n
5
10
0)
p
V
al
ue
A
ge
56
.5
(S
D
8.
6)
49
.2
(S
D
9.
4)
53
.5
(S
D
8.
9)
,
0.
00
1
51
.4
(S
D
6.
9)
46
.7
(S
D
7.
6)
49
.1
(S
D
6.
3)
,
0.
00
1
B
od
y
m
as
s
in
de
x
25
.9
(S
D
5.
1)
23
.8
(S
D
4.
0)
23
.5
(S
D
5.
1)
,
0.
00
1
26
.3
(S
D
5.
4)
24
.0
(S
D
4.
0)
24
.0
(S
D
4.
8)
,
0.
00
1
P
ro
po
rt
io
n
of
sm
ok
er
s
13
9/
17
7
(7
8.
5%
)
12
5/
16
4
(7
6.
2%
)
87
/1
00
(8
7.
0%
)
.
0.
1
90
/1
13
(7
9.
6%
)
10
5/
13
6
(7
7.
2%
)
61
/7
3
(8
3.
6%
)
.
0.
1
A
ve
.a
lc
oh
ol
co
ns
um
.
5
dr
in
ks
/d
ay
10
dr
in
ks
/d
ay
9
dr
in
ks
/d
ay
,
0.
00
1
5.
5
dr
in
ks
/d
ay
11
dr
in
ks
/d
ay
11
dr
in
ks
/d
ay
,
0.
00
1
H
yp
er
te
ns
io
n
64
/2
06
(3
1.
1%
)
23
/1
73
(1
3.
3%
)
20
/9
8
(2
0.
4%
)
,
0.
00
5
37
/1
30
(2
8.
5%
)
19
/1
44
(1
3.
2%
)
11
/6
9
(1
5.
9%
)
,
0.
00
5
D
ia
be
te
s
57
/2
06
(2
7.
7%
)
31
/1
73
(1
7.
9%
)
25
/9
8
(2
5.
5%
)
,
0.
05
30
/1
30
(2
3.
1%
)
27
/1
44
(1
8.
8%
)
22
/6
9
(3
1.
9%
)
,
0.
05
A
cu
te
M
I
80
(2
7.
8%
)
1
(0
.4
%
)
4
(2
.9
%
)
,
0.
00
01
47
(2
6.
4%
)
0
(0
%
)
2
(2
.0
%
)
,
0.
00
01
O
ld
in
fa
rc
t
sc
ar
12
1
(4
2.
0%
)
15
(5
.5
%
)
13
(9
.3
%
)
,
0.
00
01
63
(3
5.
4%
)
7
(3
.0
%
)
4
(4
.0
%
)
,
0.
00
01
G
en
ot
yp
e
A
1/
A
1
20
3
18
4
10
0
.
0.
1
12
0
15
7
65
.
0.
1
A
2/
A
1
68
68
25
47
63
18
A
2/
A
2
10
6
2
8
5
2
M
I
5
m
yo
ca
rd
ia
li
nf
ar
ct
io
n;
SD
5
st
an
da
rd
de
vi
at
io
n.
1318 Mikkelsson et al. JACC Vol. 36, No. 4, 2000
GPIIIa PlA1/A2 Polymorphism and Sudden Cardiac Death October 2000:1317–23
a macroscopic organizing thrombus was observed in 14
cases and an acute thrombus without AMI in 5 cases. An
additional 10 men had suffered an acute, fatal occluding
coronary thrombosis without histologic features of MI, due
to their short survival time. These 10 men were included
among MI cases. Of a total of 194 men with MI, 68 men
(35.1%) were associated with coronary thrombosis, whereas
MI in the remaining 126 men (64.9%) was due to severe
coronary stenosis without thrombosis; acute thrombus was
found in 39 cases. The prevalence of men with SCD due to
CHD is shown in Figure 1. Men with thrombosis and MI
were, on average, younger (mean 56.6 years) compared to
men with MI in the absence of thrombosis (mean 59.2
years). Acute MI was more often found and an old infarct
scar less often found in men with thrombosis compared with
men having MI without thrombosis (data not shown).
DNA extraction and PlA1/A2 genotyping. In the 1981–
1982 series DNA was extracted from paraffin-embedded
samples of cardiac muscle using a method described by Isola
et al. (50). In the 1991–1992 series DNA isolation was
performed from frozen (270°C) cardiac muscle samples by
the standard phenol-chloroform method. The polymor-
phism of cytosine/thymidine in exon II of the glycoprotein
IIIa gene was detected by PCR and restriction digestion.
Primer sequences and PCR protocol have been previously
described in detail (29). Genotyping was successful in 666
cases. In the 1991–1992 series 99.7% of the samples were
successfully genotyped, whereas 91.8% of the samples from
the 1981–1982 series could be genotyped.
Risk factors of coronary artery disease and sudden death.
A spouse, relative or close friend of the deceased could be
interviewed in 500 (71.4%) cases. Questions delineated past
and recent smoking and drinking habits as well as previous
illnesses. On the basis of these interviews, men were
classified as smokers (n 5 353) and nonsmokers (n 5 88).
Ex-smokers (n 5 67) were included in the class of smokers
for statistical analysis. Average daily alcohol consumption of
the deceased was calculated from information given by the
interviewed persons. One bottle of beer, glass of wine and
shot of spirits were each considered to contain 12 g of pure
alcohol and to equal one drink. On the basis of questions on
previous illnesses, 107 men had suffered from hypertension
and 113 men from diabetes.
Statistical analysis. Characteristic differences between
causes of deaths were bivariately analyzed with Student
t-tests (Table 1). Analyses of the effect of genotype on MI
with/without thrombosis and comparisons between acute
thrombosis cases and other SCD victims were based on
logistic regression, where the confounding effects of age,
body mass index, smoking, alcohol consumption (in grams),
hypertension and diabetes were taken into account by
including them in the model as covariates. We also analyzed
the trend for the prevalence of genotypes in different age
groups and groups of causes of deaths using chi-square tests
and logistic regression (Tables 2–4). All data analyses were
performed both with and without the interview data. The
computation was carried out with STATISTICA/WIN
(Version 5.0, Statsoft Inc., Tulsa, Oklahoma) and BMDP
Statistical Software on a SUN/UNIX mainframe.
RESULTS
Prevalence of PlA1/A2 alleles. Frequencies of PlA1 and
PlA2 in the genotyped population of 666 men were 0.85 and
Figure 1. Description of men who suffered SCD because of CHD.
Subgroups with and without thrombosis or MI. Gray box 5 acute
thrombosis; black box 5 organ thromb; white box 5 no thromb.
Table 2. Distribution of PlA1/A2 Genotypes in Relation to Causes of Sudden Death
<50 Years 50–60 Years >60 Years p Value
for
TrendA1/A1 A21 A1/A1 A21 A1/A1 A21
All causes 173 79 (31.3%) 169 64 (27.5%) 145 36 (20.0%) , 0.05
SCD 41 27 (39.7%) 79 28 (26.2%) 83 23 (21.7%) , 0.05
Violent 100 40 (28.6%) 57 28 (32.9%) 27 6 (18.2%) . 0.1
Other diseases 32 12 (27.3%) 33 8 (19.5%) 35 7 (16.7%) . 0.1
SCD 5 sudden cardiac death.
Table 3. Distribution of PlA1/A2 Genotypes in Men with
Acute Fatal Thrombosis and Men With SCD Without
Acute Thrombosis
<60 Years >60 Years
A1/A1 A21 A1/A1 A21
SCD, acute thromb. 11 17 (60.7%) 9 2 (18.2%)
SCD, no acute thromb. 109 38 (25.9%) 74 21 (22.1%)
SCD 5 sudden cardiac death.
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0.15, respectively. The allele frequencies were almost iden-
tical in both autopsy series. Genotype frequencies were
73.1% for PlA1/A1, 24.2% for PlA1/A2 and 2.7% for PlA2/A2.
Frequencies of PlA1 and PlA2 were identical (0.85 vs. 0.15)
in the subpopulation with interview data. On population
basis the frequency in Finland of A2 allele is 0.14 and the
frequency of A2-positive genotypes is 26.5% (51), which is
almost identical to the frequencies in our series, 0.15% and
26.9%, respectively.
Association of PlA1/A2 genotypes with the causes of
sudden death. The frequency of A2 allele was similar
among cases of SCD, violent deaths and deaths due to other
diseases (p . 0.1). However, the frequency of the A2 allele
decreased with age in the series (p , 0.05). Frequency of the
A2 allele in men dying suddenly under the age of 50 (n 5
252) was 31.3%, and it decreased to 20.0% in men over 60
(n 5 181) (Tables 1 and 2). This decrease was observed only
among cases of SCD, in whom the A2 allele was found in
39.7% of the 68 men under 50, in 26.2% of the 107 men
between 50 and 60 and in 21.7% of the 106 men over 60
(p , 0.05). In cases of violent deaths and deaths due to
other diseases, the frequency of men with A2 allele did not
change significantly with age (p . 0.1) (Table 2). When we
compared the groups with different causes of death in men
under 50, the A2 allele was associated with an increased risk
of SCD compared to death due to violent causes or other
diseases (OR 2.5, 95% CI 1.2 to 5.3; p 5 0.01).
Coronary thrombosis and PlA1/A2 polymorphism. In
cases of fatal acute thrombosis (n 5 39), 19 (48.7%) were
carriers of A2 allele compared with 59 (24.4%) of the 242
men with SCD without acute thrombosis (OR 3.4, 95% CI
1.5 to 6.3; p , 0.01). In men under 60, 17 (60.7%) of the
28 men with acute fatal thrombosis had the A2 allele and it
was found in 38 (25.9%) of the 147 men with SCD without
acute thrombosis (OR 4.6, 95% CI 2.0 to 11.2; p , 0.0005)
(Table 3). Thirty (44.8%) of the 67 men with MI and acute
or old coronary thrombosis carried the A2 allele, whereas it
was found in 25 (20.3%) of the 123 men with MI in the
absence of thrombosis (OR 3.6, 95% CI 1.4 to 9.2; p 5
0.005). In men under 60, 23 (60.5%) of the 38 men with MI
and coronary thrombosis possessed the A2 allele compared
with 11 (17.5%) of the 63 men with MI in the absence of
thrombosis (OR 8.0, 95% CI 2.3 to 28.2; p 5 0.001) (Table
4). The associations of the A2 allele with thrombosis
weakened in men over 60 (p 5 0.1).
Even though the number of A2 homozygotes was too
small for conclusions, coronary thrombosis was present in
three of the four A2 homozygotes with MI, whereas it was
found in 37 (27.4%) of the 135 A1 homozygotes with MI
(p 5 0.07; OR 7.95, 95% CI 0.8 to 80.5). The above
associations of the A2 allele with thrombosis were similar
both in men with interview data on smoking, alcohol
consumption, diabetes and hypertension and in the ex-
cluded men without interview data (data not shown).
The results were similar and independently significant in
both the 1981–1982 and the 1991–1992 series. The A2
allele was found in 19 (42.2%) of the 45 men with MI due
to thrombosis in the 1981–1982 series and in 11 (50%) of
the 22 men with MI due to thrombosis in the 1991–1992
series (29), whereas the A2 allele was present in 19 (25.0%)
of the 76 men with MI in the absence of thrombosis in the
1981–1982 series and in 6 (12.8%) of the 47 men with MI
in the absence of thrombosis in the 1991–1992 series (29).
DISCUSSION
Major findings of the study. We found that the A2 allele
of the PlA1/A2 polymorphism of the gene for GPIIIa was
associated with acute fatal coronary thrombosis. The A2
allele was also overrepresented in individuals with MI and
acute or old thrombosis. These associations were especially
strong in men under the age of 60. In addition, the A2
carriers under the age of 50 were at an increased risk of
SCD. This suggests that the A2 allele may be a possible
predictor of SCD due to coronary thrombosis in early
middle age or is in linkage disequilibrium with another
nearby gene.
Genetics of MI and SCD. The role of genetic factors is
considered to be very important in sudden cardiac death and
first MI; positive family history is an independent risk factor
for primary cardiac arrest (52) and sudden death (6,9). The
importance of genetic factors is also supported by the fact
that the incidence of first MIs has not decreased, even
though effective primary prevention has resulted in de-
creased CHD morbidity and mortality (53).
Previous studies on association of the PlA polymorphism
with MI. Possible explanations for differences in previous
studies on MI include the fact that in studies in which an
association was found, the risk is increased in younger men
(30–32,34,37), cases of Q-wave infarction (33,37) and
smokers (37). Smoking has been suggested to interact with
the PlA polymorphism (37,54). Almost all of our MI cases
were smokers. Zotz et al. (34) also found that although the
A2 allele is strongly associated with MI in young men in the
Table 4. Distribution of PlA1/A2 Genotypes in Men With MI With/Without Thrombosis in
Different Age Groups
<50 Years 50–60 Years >60 Years
A1/A1 A21 A1/A1 A21 A1/A1 A21
MI, thrombosis 6 10 (62.5%) 9 13 (59.1%) 22 7 (24.1%)
MI, no thrombosis 16 3 (15.8%) 36 8 (18.2%) 46 14 (23.3%)
Cases with acute fatal thrombosis in the absence of MI morphology due to short survival time are included in men with MI and
thrombosis. MI 5 myocardial infarction.
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acute phase, no association was found when they analyzed
the survivors of MI one year after the event. This is the most
likely explanation for the lack of effect in the studies
(38,39,44,45) in which MI cases were survivors analyzed
from six months up to several years after the event.
Anderson et al. (36) also found a modest association of
the PlA polymorphism with MI, and they had both acute
cases and survivors as their case patients. In the study by
Marian et al. (46) there was a trend towards an association,
but no subgroup analysis was performed for their MI
patients under 60. The explanation for the lack of effect in
the studies by Osborn et al. (40) and Scaglione et al. (41)
remains unclear, although one-third of the cases in the latter
study had non-Q-wave infarction. Sperr et al. (43) studied
only CHD patients. Control patients differed significantly
from the normal population in the study by Samani et al.
(47). The study by Ridker et al. (42) has previously been
criticized for the low prevalence of traditional risk factors
and low incidence of MI cases (55). The PHS study
population is also ethnically mixed (56), which is a major
confounder in genetic association studies (57). In addition,
half of the men were randomized to aspirin, which is a
confounder as it has been shown that platelets of men with
the A2 allele are more responsive to the effect of aspirin than
are platelets of A1 homozygotes (25,58).
Basic pathology of MI in relation to association studies
of prothrombotic factors. We believe that some of the
differences in the previous results may also be due to
heterogeneity in the basic pathology of MI. Transmural
(often Q-wave) infarction is nearly always caused by an
occluding fibrin-rich (red) coronary thrombus
(17,19,20,59), whereas in most (75% to 80%) patients with
unstable angina pectoris who develop non-transmural (usu-
ally non-Q-wave) infarction, occluding fibrin-rich thrombi
are absent (17,19,20,60,61) and when thrombotic material
is present (in approximately 50% of cases), it is often
composed of platelets (mural white thrombus) adhered to
preexisting stenotic lesions (16,18,19,60). Q-wave infarc-
tion is a markedly more frequent MI type in early middle
age (62,63) often because of the lack of hemodynamically
significant collateral vessels (18,64). This and the limita-
tions and strengths of the autopsy study are discussed in our
previous study (29). The absence of thrombosis in many of
our MI cases may be due to this difference, but it is also
possible that in some cases of old MI there has been a
thrombus that has been totally recanalized. However, in
cases of acute MI this is highly unlikely, as complete
spontaneous reperfusion usually takes weeks to occur
(65,66).
Possible use of the A2 allele as a risk marker in primary
prevention of MI/SCD. In the light of the two findings of
the A2 allele being a risk factor for MI and possibly SCD,
especially in early middle age, and platelets of men with the
A2 allele responding to aspirin up to 10 times as effectively
as those of men with A1 homozygotes (25,58), it seems
possible that young asymptomatic men (especially smokers)
with the A2 allele might benefit from aspirin as primary
prevention of MI/SCD, as the A2 allele seems to represent
an otherwise uncontrolled risk factor for coronary events
(67,68). However, the A2 allele as a risk factor is likely to be
most detrimental in a cluster of other risk factors such as
smoking and dyslipidemia. The PlA1/A2 polymorphism may
represent one factor in the future screening protocol of
prothrombotic genetic markers used to evaluate risks in
middle-aged men with family history of MI/SCD as well as
those with clustering of conventional risk factors.
Conclusions. We conclude that the PlA2 allele of GPIIIa is
strongly associated with coronary thrombosis and may
predict the risk of SCD in early middle age. This association
of A2 allele with coronary thrombosis may explain why the
A2 allele is overrepresented in hospital series of young
patients with impending Q-wave infarctions.
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